Generate:Biomedicines vs Isomorphic Labs (2026)
The two most talked about generative protein companies, and the quieter one has gone considerably further. Generate designs protein therapeutics de novo, with a public listing that forced detailed disclosure of the platform, the pipeline and the economics, the strongest transparency posture in this category, and clinical stage assets behind it. Isomorphic has the more celebrated lineage, descending from the structure prediction work that changed the field, and a unified design engine spanning structure, binding, affinity and antibody modelling, with named pharmaceutical collaborations. It also has no software to license, no published method behind the commercial engine and no molecule in a human being yet. Pedigree against pipeline, and for a partner deciding where to place a programme, the pipeline is the evidence.
- The model generates novel protein structures and sequences rather than filtering natural scaffolds, so the design is the origin of the molecule rather than a screen applied to it.
- The regulatory and clinical position is the most advanced in this category alongside one peer, with a public listing forcing detailed disclosure of the platform and pipeline.
- Transparency is the strongest in this category, which is a direct counterexample to the closed posture common among well funded discovery companies.
- The lineage is the strongest in structure prediction and the engine unifies structure, ligand binding, affinity and antibody interaction modelling in one system.
- Named multi target discovery collaborations tell a partner what working with the company actually involves.
- Designs enter a pharmaceutical partner's own development process, so the oversight is structurally the partner's rather than internal.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Generate:Biomedicines and Isomorphic Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Generate:Biomedicines | Isomorphic Labs |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2018 | 2021 |
| Headquarters | Somerville, MA | London, United Kingdom |
| Website | generatebiomedicines.com | isomorphiclabs.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Generate:Biomedicines its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Isomorphic Labs, Generate:Biomedicines grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Isomorphic Labs its top capability grade on AI Centrality. Set against Generate:Biomedicines, Isomorphic Labs does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Generate:Biomedicines or Isomorphic Labs?
The AI Health Index grades Generate:Biomedicines higher than Isomorphic Labs on every axis that separates them, several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Isomorphic Labs does not grade higher on any scored axis.
Where do Generate:Biomedicines and Isomorphic Labs differ most?
The widest separation the AI Health Index records between Generate:Biomedicines and Isomorphic Labs is on Model and Technology Transparency, where Generate:Biomedicines grades A and Isomorphic Labs grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Generate:Biomedicines and Isomorphic Labs grade the same?
The AI Health Index grades Generate:Biomedicines and Isomorphic Labs the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Generate:Biomedicines and Isomorphic Labs not disclosed?
At the last review, at least one of Generate:Biomedicines and Isomorphic Labs published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
The disclosure asymmetry is the story here. One company is publicly listed with a filed registration statement describing the platform, the pipeline and the economics, and no molecule from the other has entered a human, with first in human work targeted for the end of 2026 and no published method or benchmark behind the commercial engine. Neither publishes a security attestation.
For protein design specifically, the governance question is biosecurity rather than bias, and neither publishes a release policy or an intended use statement for models capable of generating novel functional proteins.